Delivering Pharmaceutical Innovations Domestically and Globally
Toward Realizing the JPMA's Vision for 2035Our activities are centered on the three pillars of Innovation, Access, and Trust.
Consistently produce innovations to benefit health spans and the economy
-
Drug Evaluation Committee
The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)
-
Drug Evaluation Committee
Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.
Bring innovative new drugs to the public more quickly to enhance health security
Commit to ethical conduct and transparency to foster trust in the pharma industry
-
News Release Drug Evaluation Committee
3 organizations have produced and released educational materials for the general public on "Don't believe everything you read" in the medical and health fields.
-
Pharmaceutical Industrial Policy Committee
The World of Drugs in the Language of the Next Generation
-
JPMA Newsletter Latest Issue No.228|Report on the 2nd Co-creation Meeting
-
Event Report: Updated April 2 "JPMA Media Forum" was held.
-
DATA BOOK 2026" is now available.
-
Scientific and Practical Requirements for Drug Candidate Substances for Companies ~Statement of TPP
-
JPMA's Vision for 2035" and "JPMA's Policy Proposals for 2025" released on Feb. 26, 2025
Updates
-
Drug Evaluation Committee
The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)
-
Drug Evaluation Committee
Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.
-
Biopharmaceutical Committee
Analysis of Application Materials for Regenerative Medicine Product Approval (Life Cycle Management Information)" is available.
-
News Release Drug Evaluation Committee
3 organizations have produced and released educational materials for the general public on "Don't believe everything you read" in the medical and health fields.
-
Drug Evaluation Committee
"Don't "Take Your Belief" in Medical and Health Information!" Educational materials (jointly by three organizations)" is now available.
-
Quality & Technology Committee
Q&A on Commercial Production Digital Transformation (DX) Promotion Task Force (TF) Case Studies" is now available.
-
News Release Drug Evaluation Committee
3 organizations have produced and released educational materials for the general public on "Don't believe everything you read" in the medical and health fields.
-
Announcement Public Affairs Committee
The JPMA website (top page) has been renewed.
-
Announcement Code Compliance Committee
Revision of Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
-
Announcement
Business Policy, Business Plan, and Implementation Plan" for FY2026 is now available.
-
News Release
Election of New Board Members
-
Announcement
DATA BOOK 2026" is now available.
-
Drug Evaluation Committee
The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)
-
Drug Evaluation Committee
Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.
-
Biopharmaceutical Committee
Analysis of Application Materials for Regenerative Medicine Product Approval (Life Cycle Management Information)" is available.
-
News Release Drug Evaluation Committee
3 organizations have produced and released educational materials for the general public on "Don't believe everything you read" in the medical and health fields.
-
Drug Evaluation Committee
"Don't "Take Your Belief" in Medical and Health Information!" Educational materials (jointly by three organizations)" is now available.
-
Quality & Technology Committee
Q&A on Commercial Production Digital Transformation (DX) Promotion Task Force (TF) Case Studies" is now available.
-
Public Affairs Committee Event Report
Report on the JPMA Media Forum
-
Pharmaceutical Industrial Policy Committee Event Report
JPMA Rare Disease Day 2026 Symposium" Report Video and Report are now available.
-
International Affairs Committee Event Report
Report on "The 5th Japan-Vietnam Joint Symposium" is now available.
-
Public Affairs Committee Event Report
JPMA Presidents Press Conference" is now available.
-
Biopharmaceutical Committee Event Report
Report on "CMC Strategy Forum Japan 2025" is now available.
-
International Affairs Committee Event Report
The Third Annual Neglected Tropical Diseases Contest is Held
About JPMA
Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders.
Each committee and specialized body bring together a diverse pool of talent - from young professionals to experienced experts - working across organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.
JPMA's Vision
Consistently produce innovations to benefit health spans and the economy
- Pharmaceutical innovations
- Leading-edge scientific technology
- Pharmaceutical manufacturing technology
- Domestic manufacturing infrastructure
- Making Japan a science and technology powerhouse
- Fostering highly skilled talent
- PPI/E
- Drug discovery that involves patients and the public
- Co-creation
- Drug discovery ecosystem
- Job creation
- Extending health spans
- Well being
- Pharma as a core industry
- Economic growth
Bring innovative new drugs to the public more quickly to enhance health security
- A social security system that gives patients swift access to “the latest treatments” and stable access to “global-standard treatments”
- Positive investment cycle
- Building an attractive domestic market
- Drug pricing that properly factors in the worth of innovation
- Health security for Japan
Commit to ethical conduct and transparency to foster trust in the pharma industry
- Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
- Overcome the social challenges raised by Japan’s aging population
- Ethical soundness, code of behavior, and transparency
- Boost public literacy in health and medicine
- Social significance of pharmaceuticals and the pharma industry
- Encourage the public and younger people to enter the pharma industry
- Climate change
- Environmental issues
Member Companies
The JPMA has 68 R&D-oriented JPMA member companies (as of April 1, 2026).
